Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 149 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Aug 22, 2026 to Aug 13, 2027v149
  2. 39 versions Re-verified since Feb 14, 2026, no change to tracked fieldsv110-v148
  3. Study completion date: Aug 22, 2025 to Aug 22, 2026v109
  4. 2 versions Re-verified since Feb 19, 2025, no change to tracked fieldsv107-v108
  5. Study completion date: Aug 22, 2024 to Aug 22, 2025v106
Show 6 earlier versionsHide 6 earlier versions
  1. 4 versions Re-verified since Sep 12, 2023, no change to tracked fieldsv102-v105
  2. Study completion date: Aug 22, 2024v101
  3. Re-verified, no change to tracked fieldsv100
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib hydrochloride and chemotherapy may kill more tumor cells.
Trial Details
NCT Number NCT00045201
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Adult Solid Neoplasm
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov